GSK (LON:GSK) Insider Sells £336,506.40 in Stock

GSK plc (LON:GSK) insider Luke Miels sold 15,579 shares of GSK stock in a transaction on Friday, February 13th. The shares were sold at an average price of GBX 2,160, for a total value of £336,506.40.

Luke Miels also recently made the following trade(s):

• On Monday, February 9th, Luke Miels sold 4,549 shares of GSK stock. The shares were sold at an average price of GBX 2,211, for a total value of £100,578.39.

GSK Stock Performance

Shares of GSK stock opened at GBX 2,237.43 on Friday. The business has a 50-day simple moving average of GBX 1,915.02 and a 200-day simple moving average of GBX 1,716.42. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. GSK plc has a one year low of GBX 1,242.50 and a one year high of GBX 2,282. The company has a market cap of £90.28 billion, a PE ratio of 16.82, a P/E/G ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK) last issued its quarterly earnings results on Wednesday, February 4th. The company reported GBX 172 earnings per share (EPS) for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. On average, equities research analysts forecast that GSK plc will post 175.980975 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Berenberg Bank lifted their price target on GSK from GBX 1,600 to GBX 1,660 and gave the stock a “hold” rating in a report on Monday, November 24th. Shore Capital Group restated a “buy” rating and set a GBX 2,300 target price on shares of GSK in a research note on Wednesday, February 4th. Citigroup increased their price target on shares of GSK from GBX 1,900 to GBX 2,250 and gave the company a “buy” rating in a research note on Monday, February 9th. UBS Group restated a “neutral” rating and set a GBX 1,940 price objective on shares of GSK in a research report on Friday, January 23rd. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 2,100 target price on shares of GSK in a research report on Wednesday, January 7th. Three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, GSK has an average rating of “Hold” and a consensus price target of GBX 1,917.86.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.